Edition:
United States

Biosynex SA (ALBIO.PA)

ALBIO.PA on Paris Stock Exchange

3.37EUR
15 Dec 2017
Change (% chg)

€0.00 (+0.00%)
Prev Close
€3.37
Open
€3.33
Day's High
€3.37
Day's Low
€3.33
Volume
1,248
Avg. Vol
3,664
52-wk High
€5.44
52-wk Low
€2.17

Chart for

About

Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings.... (more)
No analyst recommendations are available for .

Overall

Beta: 1.25
Market Cap(Mil.): €30.79
Shares Outstanding(Mil.): 9.14
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.10 16.04
EPS (TTM): -- -- --
ROI: -- 13.32 34.69
ROE: -- 19.86 15.46

BRIEF-Biosynex H1 net income swings to 1‍​ million euros

* H1 NET INCOME EUR 1‍​ MILLION VERSUS LOSS OF EUR 0.1 MILLION AT END DEC 2016

Oct 19 2017

BRIEF-Biosynex places 568,442‍​ new shares with nominal value of 0.10 euro

* HAS PLACED 568,442‍​ NEW SHARES WITH NOMINAL VALUE OF EUR 0.10

Jul 26 2017

BRIEF-Biosynex announces private placement of 2 million euros

* ANNOUNCES PRIVET PLACEMENT OF OF EUR 2 MILLION IN NEW SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 25 2017

BRIEF-Biosynex H1 revenue up at 15.6 million euros

* H1 REVENUE EUR 15.6 MILLION VERSUS EUR 13.3 MILLION YEAR AGO

Jul 24 2017

BRIEF-Biosynex raises 1.96 million euros in capital increase

* PLACEMENT OVERSUBSRCRIBED BY 213% Source text: http://bit.ly/2ug41VT Further company coverage: (Gdynia Newsroom)

Jul 21 2017

BRIEF-Biosynex launches capital increase for a maximum amount of 1.96 million euros

* LAUNCHES CAPITAL INCREASE GUARANTEED BY FOUNDING SHAREHOLDERS WITH PREFERENTIAL SUBSCRIPTION RIGHTS FOR MAXIMUM AMOUNT OF € 1.96 MILLION

Jul 03 2017

Earnings vs. Estimates